Jade Biosciences, Inc.(JBIO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
JBIO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Jade Biosciences, Inc. (JBIO), a Healthcare sector company. JBIO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of JBIO by reported 13-F value include FMR, Jupiter Topco, Fairmount Funds Management, based on the most recent SEC filings. JBIO trades on the Nasdaq exchange and files with the SEC under CIK 1798749. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Jade Biosciences, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-55.8M
ROIC
Q2 2026
-53.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-83.0% YoYOperating Income
-52.2% YoYEPS (Diluted)
-30.7% YoYTotal Assets
+380.5% YoYOp. Cash Flow
-33.0% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-127.4M -83.0% | $-69.6M +7.8% | $-75.5M -46.6% | $-51.5M -124.3% | $-23.0M -138.9% | $-9.6M |
| Operating Income | $-113.5M -52.2% | $-74.6M +8.4% | $-81.4M -52.9% | $-53.2M -131.2% | $-23.0M -159.0% | $-8.9M |
| EPS (Diluted) | $-3.19 -30.7% | $-2.44 +15.0% | $-2.87 -36.7% | $-2.10 -12.3% | $-1.87 | — |
| Total Assets | $349.8M +380.5% | $72.8M -42.9% | $127.4M -5.8% | $135.3M -22.8% | $175.4M +3619.3% | $4.7M |
| Operating Cash Flow | $-94.7M -33.0% | $-71.2M -25.4% | $-56.8M -45.1% | $-39.1M -42.8% | $-27.4M -248.6% | $-7.9M |
| Free Cash Flow | $-94.9M | — | $-56.9M -44.8% | $-39.3M -42.6% | $-27.6M | — |
Get alerted when JBIO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Jade Biosciences, Inc. including:
Top Institutional Holders of JBIO
FMR LLC
$202.8M9,126,877 shJupiter Topco LLC
$139.4M6,273,262 shFairmount Funds Management LLC
$101.2M4,553,494 shRA CAPITAL MANAGEMENT, L.P.
$81.6M3,671,083 shVR Adviser, LLC
$71.6M3,220,364 shBellevue Group AG
$67.9M3,057,996 shParadigm Biocapital Advisors LP
$63.5M2,857,405 shBlackRock, Inc.
$62.2M2,801,451 shFRANKLIN RESOURCES INC
$62.0M2,792,080 shSTATE STREET CORP
$51.9M2,335,285 sh
| Fund | Value | Shares |
|---|---|---|
| FMR LLC | $202.8M | 9,126,877 |
| Jupiter Topco LLC | $139.4M | 6,273,262 |
| Fairmount Funds Management LLC | $101.2M | 4,553,494 |
| RA CAPITAL MANAGEMENT, L.P. | $81.6M | 3,671,083 |
| VR Adviser, LLC | $71.6M | 3,220,364 |
| Bellevue Group AG | $67.9M | 3,057,996 |
| Paradigm Biocapital Advisors LP | $63.5M | 2,857,405 |
| BlackRock, Inc. | $62.2M | 2,801,451 |
| FRANKLIN RESOURCES INC | $62.0M | 2,792,080 |
| STATE STREET CORP | $51.9M | 2,335,285 |
More Healthcare Companies
View all Healthcare →Put JBIO on your watchlist
Track score changes the day Jade Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is JBIO a good stock to buy?
13F Pro's AI-powered analysis of Jade Biosciences, Inc. (JBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JBIO are available on the JBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. JBIO is classified as a small company.
Which hedge funds own JBIO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Jade Biosciences, Inc.'s investment landscape.